Pfizer appears to be speeding toward a crucial early FDA approval for palbociclib, a breast cancer treatment with blockbuster potential, pivoting from its failed bid for AstraZeneca and building up an oncology pipeline of its own.

…read more

Source: Pfizer nears a new dawn in oncology with AstraZeneca in the rearview


0 No comments